WondFo make a large number of diagnostic tests including an...

WondFo make a large number of diagnostic tests including an influenza rapid test.

These tests can be used in conjunction with each other to confirm one virus for the purpose of helping exclude the other.

WondFo's flowchart for a full diagnostic work-up of patients is comprehensive. Extremely comprehensive.

https://en.wondfo.com.cn/1-m2-poct/

Subject to Maria's next announcement the wheel is still spinning on the future the use and demand for WondFo Covidid-19 ab POCTS in Australia. It was previously announced that a locally based assessments of the POCT were to be completed and we have seen calls in the media by Cellmid post-COVID-19 volunteers to enrol in the study. And as noted in a post above, Peter Doherty was always going to complete an independent post-implementation review and report his results back to the TGA.

These are all known knowns. Cellmid is following an expected fast track approval pathway for new medical devices. Cellmid is completing what appears to be a limited Phase 1 (like) study prior to (or in parallel with) initial distribution of the test. A Phase 2 like follow-up will happen later. This is how the industry operates.

Cellmid itself can't anticipate end results of the scheduled studies or government policy. As posted some time back I was pleased to learn that only 12,000 kits were included in the initial order. Keeping a small footprint at the beginning mitigates risk.

cheers